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Introduction
Cancer is one of the main causes of death worldwide 
(Keyghobadi et al., 2015). It is predicted that by 2025, the 
incidence of cancer raises 45% in developing countries 
(Amoori et al., 2014) . Based on the GLOBOCAN report, 
14090 new cases of cancer annually occur in the world and 
8202 people per year die due to cancer in the world (Ferlay 
et al., 2015). In some countries, cancer is the second 
leading cause of death among all of causes of death, but 
in developing countries, including Iran, cancer is a major 
public health problem among non-communicable diseases 
So that after cardiovascular diseases and accidents is the 
third leading cause of death in Iran (Sadjadi et al., 2007; 
Mehrabani et al., 2008; Amoori et al., 2014). 
One of the major cancers is prostate cancer so that it is 
second most common cancer in men in the world (Sadjadi 
1Department of Epidemiology, Biostatistics, school of public health, Tehran University of Medical Sciences, Tehran, 2Department of 
Epidemiology, Biostatistics, School of public health, Hamadan University of medical sciences, Hamadan, 3School of Allied Medical 
Sciences, Tehran University of Medical Sciences, 4Minimally Invasive Surgery Research Center, Iran University of Medical Sciences, 
5Students’ Scientific Research Center, Tehran University of Medical Sciences, 6Endometriosis Research Center, Iran University of 
Medical, Tehran, 7Department of internal medicine, Zabol University of medical sciences, 8Zabol University of medical sciences, 
Zabol, 9Shahid Beheshti University of Medical Sciences, Tehran, Iran, Iran  *For correspondence: alesaleh70@yahoo.com 
Abstract
 Background: Prostate cancer is second most common cancer in men overall in the world, whereas it is the 
third most common cancer in men and the sixth most common cancer in Iran. Few studies have been conducted 
on the epidemiology of prostate cancer in Iran. Since ethnicity of Iranian men is different from Asian people and 
given the epidemiologic and demographic transition taking place in Iran, this study aimed to investigate trends 
of incidence and morphology of prostate cancer during 2003 - 2008 in the country. Materials and Methods: Data 
were collected retrospectively reviewing all new prostate cancer patients in the Cancer Registry Center of the 
Health Deputy for Iran during a 6-year period. Also carcinoma, NOS and adenocarcinoma, NOS morphology 
were surveyed. Trends analysis of incidence and morphology was by joinpoint regression. Results: During the 
six years a total of 16,071 cases of prostate cancer were recorded in Iran. Most were adenocarcinomas at 95.2 
percent. Trend analysis of incidence (ASR) There was a significant increase incidence, with annual percentage 
change (APC) of 17.3% and for morphology change percentage trends there was a significant decrease in 
adenocarcinoma with an APC of -1.24%. Conclusions: Prostate cancer is a disease of older men and the incidence 
is increasing in Iran. The most common morphology is adenocarcinoma this appears to be decreasing over time. 
Due to the changing lifestyles and the aging of the population, epidemiological studies and planning assessment 
of the etiology of prostate cancer and its early detection are essential. 
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et al., 2007) and first most common cancer in American 
and European men (Bray et al., 2010), while in 2012, 1.1 
million men suffered from prostate cancer in the world, 
about 70% in developing countries (Ferlay et al., 2015). 
Almost 42% of prostate cancer cases occur in men over 50 
years (Hosseini et al., 2007) and most cases often are seen 
after 60 years (Pourmand et al., 2007; Pakzad et al., 2015). 
Few studies have been conducted on the epidemiology 
of prostate cancer in Iran (Radmard, 2010), whereas it 
is the third most common cancer in men and the sixth 
most common cancer in Iran (Goya, 2007), Prostate 
cancer has a different geographical distribution so that in 
Asian countries, including Iran, is lower than in Western 
countries (Hosseini et al., 2007; Autorino et al., 2009; 
Ferlay et al., 2015). There also is the same distribution 
of the cancer in Iran, as the data recorded showed that 
standardized incidence in 2000 in Ardabil was 3.5 per 
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100,000 people and other studies have reported the 
incidence of 15.6 per 100,000 people in men (Radmard, 
2010), While a study conducted in the Fars province 
at the same time indicated that the cancer is not one of 
the ten most common cancers (Mehrabani et al., 2008). 
Different causal factors are effective on developing the 
cancer. These factors can be age and nutrition (Pourmand 
et al., 2007). Due to changes in nutrition and also older 
population (Amoori et al., 2014), it can be expected to 
change over time the incidence of prostate cancer. A study 
based on data from 1996 to 2000 reported the incidence of 
cancer about 5.1 per 100,000 people, while the incidence 
reached to 12.5 in 2013, which represents an increasing 
trend in the incidence of prostate cancer (Ferlay et al., 
2015) Depending on the different cancer types, there are 
different morphology such as carcinoma, adenocarcinoma, 
sarcoma, and others have various percentages in different 
cancers. However, Adenocarcinoma is the most common 
type of prostate cancer and prevalent in patients older 
than 65 years (Autorino et al., 2009). Other studies have 
estimated the prevalence of this type of morphology nearly 
91.4% (Jamali and Moghadam, 1996). Since ethnicity 
Iranian men is different from Asian pepole and given 
epidemiologic and demographic transition taking place 
in Iran, this study aimed to investigate the Epidemiology 
Characteristics and Trends of Incidence and Morphology 
of Prostate Cancer, during 2003 - 2008 in Iran. 
Materials and Methods
Data source
This analytic study was done based on longitudinal 
program in Iran. The data were collected from Cancer 
Registry Center report of health deputy which is based on 
Iran ministry of health guidelines (Goya, 2007). Data were 
collected retrospectively reviewing all new prostate cancer 
patients in Cancer Registry Center of health deputy for 
Iran during a 6-year period (2003 - 2008). Prostate cancer 
was defined as ICD-O C61 (Fritz, 2000).This study Survey 
Carcinoma,NOS and Adenocarcinoma,NOS with 8010/3 
and 8140/3 morphology code, respectively. 
Statistical analysis
Age-standardized rates of cancer incidence were 
calculated by the direct standardization method, using 
the world standard population as a reference. To describe 
incidence time trends, we carried out joinpoint regression 
analysis using the software Joinpoint Regression Program, 
Version 4.1.1.1 October 2014 (Kim et al., 2000). As well 
to evaluate the morphological changes, were obtained 
the percentage allocated for kind of morphological types. 
So to analysis morphology change percentage trends for 
six year, we carried out joinpoint regression analysis 
using the software Joinpoint Regression Program. The 
analysis included logarithmic transformation of the rates, 
standard error, maximum number of one joinpoints, and 
minimum of six years between zero joinpoints. All other 
program parameters were set to default values. The aim 
of the approach is to identify possible joinpoints where 
a significant change in the trend occurs. The method 
identifies joinpoints based on regression models with 0-1 
joinpoints. In this study 0 joinpiont (Full model) was a 
significant model. The final model selected was the most 
parsimonious of these, with the estimated annual percent 
change (APC) based on the trend within each segment. 
In describing trends, the terms “significant increase” or 
“significant decrease” signify that the slope of the trend 
was statistically significant (P<0.05). All statistical tests 
were two sided. Other descriptive and analytical analysis 
using of STATA 12 software. 
Results 
During the study, 9-7% of all cancers in Iranian men 
had prostate cancer. In total, the six-year study, 16,071 
cases of prostate cancer were recorded. 79-70 year old 
age group with the highest number of cases to 6,783 
cases (42.20%), which was related to the morphology of 
adenocarcinoma, was 95% (Table1).
Most cases occur after age 50 and age 80 to 84 years, 
is the peak risk for prostate cancer. About 96% of case 
occur the age group above 50 years old that this difference 
was statistically significant (P-Value <0.05) (Figure 1).
Epidemiological trends
Joinpoint analysis showed a significant increase in the 
standardized incidence rate of prostate cancer in iran. The 
Figure 1. Change in Age-Specific Incidence (ASR) 
of Prostate Cancer between Age Group in Iran from 
2003 to 2008
	  
Table 1. Cumulative Incidence of Carcinoma and Adenocarcinoma of Prostate Cancer, According to two Types 
of Morphology and of All Age Groups, During the Years 2003 to 2008
00-09 10-19 20-29 30-39 40-49 50-59 60-69 70-79 80-80+ Unknown Total
Adenocarcinoma 0 0 11 34 172 1298 4033 6485 2895 373 15301
Carcinoma 0 0 0 0 3 16 39 65 43 2 168
Total 3 1 12 39 183 1390 4179 6783 3067 411 16071
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annual percentage change (APC) for cancer incidence was 
equal to 17.29% (CI: 11.1 to 23.9) (Table 2).
Morphological Trend
The morphology of adenocarcinoma with 15301 
cases (95.21%) and carcinoma in 168 cases (1.04%) were 
the most common morphology. Significant differences 
between the morphology of prostate cancer and the 
different age groups was not observed (P-Value>0.05) 
and nearly all the morphological occur more in older age 
(Table 1). Adenocarcinoma in 2003 and 2008, respectively, 
97.61% and 90.97% of total prostate cancer accounted. 
Dedicated to the trend of changes in most common 
morphology (adenocarcinoma) annual percentage changes 
(APC) showed a significant decrease (Table 3).
Discussion
Our findings showed that the majority of cases (96%) 
occur after 50 years and the high incidence was 80 to 84 
years .a study (Fatemah Haghighi et al., 2005) conducted 
in Birjand (East of Iran) showed more cases occur after 50 
years and prostate cancer is the most frequent in the ninth 
decade of life (80 years and above), which is consistent 
with the results of this study.
In another study in the Fars province, it also found that 
99% of cases occur in man over 50 years and the highest 
incidence of cancer is at the age of 80 years (Farahmand et 
al., 2013). A study in the Khuzestan province showed that 
more than 99% cases were 45 years and the high incidence 
was 75 to 84 years (Amoori et al., 2014). 
A another study conducted in the Babol city also 
found that the highest age of developing cancer was 70 
years (Hahiyan et al., 2003) and Basiri also showed that 
the maximum age was 70 years (Basiri et al., 2014). One 
study was conducted in Turkey showed that the maximum 
age for the incidence cancer was 75 to 79 year (Eser et al., 
2009) and Another study reported in Greece the incidence 
was 7o- to 75 years (Grivas et al., 2012), This difference 
may be due to differences in the age composition of the 
population.
As the incidence of prostate cancer increases, the age 
increases (Eser et al., 2009) and after 50 years it raises 
with a steep ascent (Muir et al., 1991; Fatemah Haghighi 
et al., 2005; Grivas et al., 2012; Farahmand et al., 2013). 
However, in another study in America it was as steep 
as after 65 years (Gronberg, 2003). In a study it was in 
Turkey 40 years (Zorlu et al., 2014)and in Greece 45 
years reported (Grivas et al., 2012). This could be due to 
racial differences and genetic and environmental factors, 
such as diet, environment, occupation, smoking, and other 
unknown risk factors.
In this study, the standardized incidence of prostate 
cancer in 2003 to 2009 was 5.4, 7.24, 9.22, 9.57, 10.91, 
and 12.80 cases per 100,000 people, respectively. 
According to the GLOBOCAN report in 2002, the age 
standardized incidence rate of prostate cancer in the 
world was 25.3 cases per 100,000 people so this rate in 
developed countries (the highest was related to United 
States (U.S) was 56.2 and in developing countries, 9.4 
cases per hundred thousand people (the minimum for 
Bangladesh) (Baade et al., 2009; Jack et al., 2010). Also 
the rate in Greece between 1999 to 2004 was 26 per 
hundred thousand people (Grivas et al., 2012),but the rate 
in 2002 have been reported about 3.5 per hundred thousand 
people in the Fars province (Masoompour et al., 2011) 
and in this study it was 5.4 per hundred thousand, which 
reflects the low rate of this cancer in the Iran compared 
to other countries.
This rate in Turkey in 2006 was equal to 22.8 (Eser 
et al., 2009)and in Greece had risen to 42 per hundred 
thousand people until 2010 (Grivas et al., 2012), Also in 
developed countries in 2008 it has increased to 62 cases 
and in the developing countries to 12 cases per hundred 
thousand people (Jemal et al., 2011) .In this study, the 
rate was 12.8 per hundred thousand people. This shows 
Table 2. Frequency, Crude and Standardized Incidence of Prostate Cancer and the Total Number of Cancer 
Cases by Sex, During The Years 2003 To 2008
The number of cases of pros-
tate cancer (men)
The total number of cases of 
cancer in men (percent)
Total cancer cases 
(men and women) CIR ASR
2003 1548 21619 (2/56) 38468 4.54 5.40
2004 2072 26743 (6/56) 47217 5.97 7.24
2005 2722 31355 (1/56) 55853 7.53 9.22
2006 2817 33770 (49/56) 59786 7.82 9.57
2007 3179 34636 (81/55) 62040 8.79 10.91
2008 3733 42279 (51/55) 76159 10.37 12.80
Table 3. Change in the Percentage Allocated to the Morphology of Carcinoma, Adenocarcinoma and Other 
Morphological Data (2008-2003)
2003 – 2008 2003 – 2006 2006 – 2008
AAPC 95% CI APC 95% CI APC 95% CI
Carcinoma 5.9 -43.1 to 97.1
Adenocarcinoma -1.4* -1.8 to -1.1 -0.2 -2.3 to 2.0 -3.3 -7.4 to 0.9
Other 42.7* 12.3 to 81.3
*APC and AAPC is significantly different from zero at alpha = 0.05
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that the country is better for the development so prostate 
cancer increases. This could be due to improved reporting 
systems in developing countries and developed countries 
versus less developed countries. Although some of this 
difference could be real. The standardized incidence rate 
in this study was lower than developed and developing 
countries. However, the increasing trend over the years 
has been globally observed. This could be due to better 
detection tests, an aging population, and a real increase 
in the world. At the same time, however, the incidence 
of prostate cancer has been decreasing in most European 
countries (Bray et al., 2010). This can be due to screening 
programs that have already been implemented in the 
community.
The highest incidence in this study occur in 2008, 
similar to the incidence in developing countries (Jemal et 
al., 2011), while in another study greatest incidence was 
16.65 in 2007 and with slight differences the incidence 
of 16.02 in 2008 was ranked as second (Farahmand et 
al., 2013). This may be due to differences in population, 
better detection methods, or whether this difference is 
real. However, the findings of this study are consistent 
with increasing incidence.
In the present study, the morphology of Adenocarcinoma 
was the most frequent type with 95.21% percent and 
carcinoma is the most common, followed by 1.04 percent. 
In a study showed that morphology with adenocarcinoma 
was greatest with 91.2 percent (Esmail Nasab N, 2007). In 
another study, the type of adenocarcinoma with 91.7% was 
allocated to the most common type (Fatemah Haghighi et 
al., 2005). General Urology by smith, stated that more than 
95% of prostate cancers were adenocarcinoma (Fatemah 
Haghighi et al., 2005). In another study based on samples 
taken in Imam Khomeini Hospital, Pathology Center (SID) 
and the center of Pathology, School of Medicine, Yazd ,the 
most common types were adenocarcinoma, 91.4%, 84.7% 
and 71%, respectively (Jamali and Moghadam, 1996). All 
these findings are consistent with each other and show that 
the most common type morphology of cancer in Iran. In 
a study in Saudi Arabia and Pakistan, adenocarcinoma 
is also the most common type morphology (Arshad and 
Ahmad, 2013; Albasri et al., 2014).
In addition to the lower prevalence of risk factors for 
prostate cancer, incomplete and the lack of comprehensive 
programs especially in the case of prostate cancer, breast, 
and colorectal cancer can be one of the main reasons for 
low as well as in developing countries (Mousavi et al., 
2009). These limitations can lead to underestimation of 
the true extent of this type of cancer (Masoompour et al., 
2011). In other studies, one of the most important factors of 
prostate cancer in developed countries was comprehensive 
review of the prostate cancer screening program with use 
of PSA (prostate specific antigen) (Jemal et al., 2011; 
Belbase et al., 2013).
Based the results of this study and other similar studies 
(Farahmand et al., 2013) have been identified in Iran that 
this type of cancer had the slight increase in the past years 
that may indicate that cancer registration data is better.
Based on these results and considering the prevalence 
of prostate neoplasms and adverse effects, it is suggested 
that most epidemiological studies in order to identify 
regional risk factors and lifestyles, application new 
screening methods for early diagnosis of latent prostate 
cancer .
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